- Home
- PHAT vs PSFE Comparison
PHAT vs PSFE Comparison
Compare PHAT & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- PSFE
- Stock Information
- Founded
- PHAT 2018
- PSFE 1996
- Country
- PHAT United States
- PSFE United Kingdom
- Employees
- PHAT N/A
- PSFE N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- PSFE Business Services
- Sector
- PHAT Health Care
- PSFE Consumer Discretionary
- Exchange
- PHAT Nasdaq
- PSFE Nasdaq
- Market Cap
- PHAT 716.5M
- PSFE 770.1M
- IPO Year
- PHAT 2019
- PSFE N/A
- Fundamental
- Price
- PHAT $11.91
- PSFE $14.16
- Analyst Decision
- PHAT Strong Buy
- PSFE Sell
- Analyst Count
- PHAT 5
- PSFE 4
- Target Price
- PHAT $16.40
- PSFE $17.38
- AVG Volume (30 Days)
- PHAT 1.1M
- PSFE 400.9K
- Earning Date
- PHAT 08-07-2025
- PSFE 08-12-2025
- Dividend Yield
- PHAT N/A
- PSFE N/A
- EPS Growth
- PHAT N/A
- PSFE N/A
- EPS
- PHAT N/A
- PSFE N/A
- Revenue
- PHAT $114,039,000.00
- PSFE $1,676,391,000.00
- Revenue This Year
- PHAT $194.40
- PSFE $3.06
- Revenue Next Year
- PHAT $103.23
- PSFE $6.77
- P/E Ratio
- PHAT N/A
- PSFE N/A
- Revenue Growth
- PHAT 1049.82
- PSFE 0.47
- 52 Week Low
- PHAT $2.21
- PSFE $10.63
- 52 Week High
- PHAT $19.71
- PSFE $26.25
- Technical
- Relative Strength Index (RSI)
- PHAT 75.25
- PSFE 59.37
- Support Level
- PHAT $9.82
- PSFE $13.02
- Resistance Level
- PHAT $11.19
- PSFE $13.98
- Average True Range (ATR)
- PHAT 0.71
- PSFE 0.78
- MACD
- PHAT 0.17
- PSFE 0.15
- Stochastic Oscillator
- PHAT 94.07
- PSFE 90.55
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.